BioCryst Pharma (NASDAQ: BCRX) reported Q1 EPS of ($2.98), $3.03 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $156.41 million versus the consensus estimate of $151.66 million.

GUIDANCE:

BioCryst Pharma sees FY2026 revenue of $635-660 million, versus the consensus of $650.2 million.

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.